Marcello Persico1, Andrea Aglitti1, Rosa Caruso1, Amalia De Renzo2, Carmine Selleri3, Catello Califano4, Ludovico Abenavoli5, Alessandro Federico6, Mario Masarone1. 1. Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy. 2. Hematology Department, Federico Secondo University of Naples, Naples, Italy. 3. Hematology Unit, University of Salerno, Salerno, Italy. 4. Hematology Department, Umberto I Hospital, Nocera Inferiore (Salerno), Italy. 5. Department of Health Sciences, University Magna Graecia, Catanzaro, Italy. 6. Hepatogastroenterology Division, University of Campania "Luigi Vanvitelli, Naples, Italy.
Abstract
The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throughout the world. The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not-and how-to treat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs). The aim of this observational study was to evaluate whether DAA antiviral treatment of DLBCL/HCV-infected patients in concomitance with chemotherapy is a safe and effective option. Twenty (13 males and 7 females) HCV genotype 1b-positive subjects, undergoing chemotherapy for DLBCL, were enrolled between June 2015 and December 2015. After informed consent, all patients underwent antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL. Complete hematological (Revised European-American Lymphoma classification, Ann Arbor, and International Prognostic Index [IPI] scores) and hepatological (viral markers, liver stiffness, and biochemical parameters) evaluations were made. A historical retrospective cohort of 101 DLBCL/HCV-positive patients not undergoing AVT was enrolled for comparison. DAA-treated and untreated patients were similar for sex distribution, IPI score, and NHL stage, and differed for age (older in treated), chemotherapy and use of AVT. Overall survival (OS) and disease-free survival (DFS) were evaluated among a 52-week of follow-up. No statistical difference was found in OS after 52 weeks (P = 0.122), whereas a statistically significant higher DFS was achieved in treated patients (P = 0.036). At the multivariate analysis, only IPI score and AVT were independently correlated with a better DFS. No differences in adverse events were reported. CONCLUSION: DAA treatment in concomitance with chemotherapy was shown to be safe and effective in influencing remission of aggressive lymphomas in HCV patients. (Hepatology 2018;67:48-55).
The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throughout the world. The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not-and how-to treat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs). The aim of this observational study was to evaluate whether DAA antiviral treatment of DLBCL/HCV-infectedpatients in concomitance with chemotherapy is a safe and effective option. Twenty (13 males and 7 females) HCV genotype 1b-positive subjects, undergoing chemotherapy for DLBCL, were enrolled between June 2015 and December 2015. After informed consent, all patients underwent antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL. Complete hematological (Revised European-American Lymphoma classification, Ann Arbor, and International Prognostic Index [IPI] scores) and hepatological (viral markers, liver stiffness, and biochemical parameters) evaluations were made. A historical retrospective cohort of 101 DLBCL/HCV-positive patients not undergoing AVT was enrolled for comparison. DAA-treated and untreated patients were similar for sex distribution, IPI score, and NHL stage, and differed for age (older in treated), chemotherapy and use of AVT. Overall survival (OS) and disease-free survival (DFS) were evaluated among a 52-week of follow-up. No statistical difference was found in OS after 52 weeks (P = 0.122), whereas a statistically significant higher DFS was achieved in treated patients (P = 0.036). At the multivariate analysis, only IPI score and AVT were independently correlated with a better DFS. No differences in adverse events were reported. CONCLUSION:DAA treatment in concomitance with chemotherapy was shown to be safe and effective in influencing remission of aggressive lymphomas in HCVpatients. (Hepatology 2018;67:48-55).
Authors: Hashem B El-Serag; Israel C Christie; Amy Puenpatom; Diana Castillo; Fasiha Kanwal; Jennifer R Kramer Journal: Aliment Pharmacol Ther Date: 2019-04-01 Impact factor: 8.171
Authors: Michele Merli; Marco Frigeni; Laurent Alric; Carlo Visco; Caroline Besson; Lara Mannelli; Alice Di Rocco; Angela Ferrari; Lucia Farina; Mario Pirisi; Francesco Piazza; Véronique Loustaud-Ratti; Annalisa Arcari; Dario Marino; Antonello Sica; Maria Goldaniga; Chiara Rusconi; Massimo Gentile; Emanuele Cencini; Francesco Benanti; Maria Grazia Rumi; Virginia Valeria Ferretti; Paolo Grossi; Manuel Gotti; Roberta Sciarra; Maria Chiara Tisi; Isabel Cano; Valentina Zuccaro; Francesco Passamonti; Luca Arcaini Journal: Oncologist Date: 2018-12-14
Authors: Julia L Marcus; Michael J Silverberg; Jennifer O Lam; Leo B Hurley; Jennifer B Lai; Varun Saxena; Suk Seo; Scott Chamberland; Charles P Quesenberry; Jamila H Champsi; Joanna Ready; Elizabeth Y Chiao Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-09-28 Impact factor: 4.090
Authors: Antonio Cuneo; Giovanni Barosi; Romano Danesi; Stefano Fagiuoli; Paolo Ghia; Alfredo Marzano; Marco Montillo; Venerino Poletti; Pierluigi Viale; Pier Luigi Zinzani Journal: Hematol Oncol Date: 2018-09-05 Impact factor: 5.271